KIT OLEG IVANOVICH,Кит Олег Иванович,FRANTSIJANTS ELENA MIKHAJLOVNA,Франциянц Елена Михайловна,SERGOSTJANTS GENNADIJ ZAVENOVICH,Сергостьянц Геннадий Завенович,KOMAROVA EKATERINA FEDOROVNA,Комарова Ека
申请号：
RU2012147176/14
公开号：
RU0002506974C1
申请日:
2012.11.06
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to medicine, oncology, therapy of patients suffering lung cancer and having contraindications to the surgical management. There are prescribed autohemochemotherapy (AHCT) that is administering chemopreparations incubated with autoblood, and radiation therapy (RT). Pre-therapeutic blood prolactin and progesterone are measured, and before the beginning of the AHCT, the patient starts taking bromocriptine 2.5 mg once a day with food besides, oxyprogesterone capronate 1 ml is administered intramuscularly twice a week every 3 days. That is followed by the AHCT course consisting of 1-3 administrations of autoblood CP, and if observing a complete tumour resorption, the surgical management to the extent of pneumoectomy is supposed to follow, while a partial resorption observed two weeks after the last auroblood CP administered, implies the RT: at first 2 Gy twice a day every 4-5 hours starting from 5 days a week to achieve a basic dose of 28 Gy. That is followed by a 2-week pause, then 4 Gy daily, 3 radiation fractions a week, 6 fractions in total, up to a total radiation dose of 52 Gy for the whole RT course. Throughout the treatment, the patient keeps taking bromocriptine and oxyprogesterone capronate with controlling the blood prolactin and progesterone values: as compared to the pre-therapeutic values, prolactin is expected to fall to the end of the treatments, while progesterone - to rise.EFFECT: method provides improving the conservative therapeutic effect in the patients of the given group: downsizing the tumour and lymph nodes until the primary tumour regresses completely by 30%, and the patients change to the resectable state improving the patients quality of life.2 ex, 1 tblИзобретение относится к медицине, онкологии, лечению больных раком легкого, которым противопоказано оперативное лечение. Проводят введение химиопрепаратов (ХП), инкубированных с аутокровью, - аутогемохимиотерапию (АГХТ) и лучевую терапию (ЛТ). При это
